Skip to content

The effectiveness of Copper bromide laser ( Dual yellow ) on inflammatory acne vulgaris in female

The effectiveness of Copper bromide laser ( Dual yellow ) on inflammatory acne vulgaris in female

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250427007
Enrollment
22
Registered
2025-04-27
Start date
2025-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to severe acne vulgaris in female patients Inflammatory acne vulgaris

Interventions

Copper bromide laser ( dual yellow ) will be applied on one side of the participants face to evaluate its efficacy and safety in the treatment of inflammatory acne.,A sham laser procedure will be perf
Experimental Device,Sham Comparator Device
Copper bromide laser,Placebo

Sponsors

Anti aging and regenerative medicine , Dhurakij Pundit University, Thailand
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Female volunteers aged between 25 and 35 years. 2. Diagnosed with moderate to severe inflammatory acne based on the IAA grading of acne severity, with at least 10 to 20 inflammatory lesions. 3. Willingness to participate and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants who are pregnant or breastfeeding. 2. Participants with underlying medical conditions that affect acne, such as adrenal tumor or polycystic ovary syndrome. 3. Participants with medical conditions that contraindicate the use of copper bromide laser, such as systemic lupus erythematosus (SLE) or photosensitivity. 4. Participants who are currently taking medications that may affect acne, such as systemic steroids, oral contraceptives, or hormone replacement therapy. 5. Participants who have changes in their acne treatment regimen during the study period, including: 5.1 Participants taking oral acne medications must have been on a stable regimen for at least 2 months prior to enrollment. 5.2 Participants using topical acne treatments must have been using them consistently for at least 6 weeks before the study. 5.3 Participants undergoing acne procedures must have received them consistently for at least 1 month before joining the study.

Design outcomes

Primary

MeasureTime frame
Acne count 3 months Counting , photograph

Secondary

MeasureTime frame
Sebum production 3 months Sebumeter,Porphyrin 3 months Visia

Countries

Thailand

Contacts

Public ContactPawaran Limphanudom

Dhurakij Pundit university

Pawa11@windowslive.com0825629564

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026